Transgene SA (EPA:TNG)
1.340
+0.050 (3.88%)
Oct 20, 2025, 2:44 PM CET
Transgene Revenue
Transgene had revenue of 4.58 million EUR in the half year ending June 30, 2025, a decrease of -3.86%. This brings the company's revenue in the last twelve months to 7.58 million, up 16.65% year-over-year. In the year 2024, Transgene had annual revenue of 6.35 million, down -19.58%.
Revenue (ttm)
7.58M
Revenue Growth
+16.65%
P/S Ratio
22.54
Revenue / Employee
51.53K
Employees
144
Market Cap
170.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.35M | -1.55M | -19.58% |
Dec 31, 2023 | 7.90M | -2.44M | -23.63% |
Dec 31, 2022 | 10.34M | -6.90M | -40.00% |
Dec 31, 2021 | 17.24M | 7.67M | 80.08% |
Dec 31, 2020 | 9.57M | -3.72M | -28.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 45.74B |
EssilorLuxottica Société anonyme | 27.24B |
Eurofins Scientific SE | 7.14B |
emeis Société anonyme | 5.77B |
Clariane SE | 5.31B |
bioMérieux | 4.12B |
Ipsen | 3.76B |
Sartorius Stedim Biotech | 2.95B |
Transgene News
- 4 weeks ago - Transgene SA (FRA:TGNA) (Half Year 2025) Earnings Call Highlights: Strategic Focus on TG4050 ... - GuruFocus
- 4 weeks ago - Half Year 2025 Transgene SA Earnings Call Transcript - GuruFocus
- 4 weeks ago - Transgene SA 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Transgene SA (TRGNF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Half Year 2024 Transgene SA Earnings Call Transcript - GuruFocus
- 2 years ago - Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 3 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire